ERBB2 and breast cancer: In addition, to determine whether prognostic or predictive differences exist between baseline and post-neoadjuvant values of these biomarkers.<h4>Methods</h4>We analyzed 801 women with early breast cancer treated with neoadjuvant chemotherapy, evaluating clinical and pathological data, survival outcomes, NLR (continuous and categorical) and SII.<h4>Results</h4>Baseline NLR was significantly higher in younger patients, in those with positive pathological nodes, and in the HER2 + /HR - subtype, while baseline SII was elevated in the triple-negative subtype.